Abstract | BACKGROUND: METHODS:
Cardiovascular disease patients with diabetes mellitus (Group A, n = 14) and nondiabetic patients with CVD only (Group B, n = 10) took atorvastatin 80 mg per day for a period of 8-10 weeks. CPCs (CD34+/CD133+/CD45-) were defined by flow cytometry, plasma levels VEGF and Ang-1 and Ang-2 by ELISA). RESULTS: Circulating progenitor cell counts increased (P < 0.001) in Group A compared with a nonsignificant change in Group B (P = 0.37). VEGF levels fell significantly in Group A (P = 0.04) but no significant change was seen in Group B (P = 0.16). Whilst Ang-1 remained unchanged (P = 0.41), Ang-2 levels increased markedly in both groups (P < 0.05). These effects were independent of LDL and total cholesterol changes but were associated with HDL changes. CONCLUSION: High-dose atorvastatin increased circulating CPCs, reduced VEGF and increased Ang-2 in patients with diabetes and CVD, providing another possible pathophysiological mechanism for the beneficial effects of statins in CVD.
|
Authors | R J Jaumdally, P K Y Goon, C Varma, A D Blann, G Y H Lip |
Journal | Journal of internal medicine
(J Intern Med)
Vol. 267
Issue 4
Pg. 385-93
(Apr 2010)
ISSN: 1365-2796 [Electronic] England |
PMID | 19754853
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiopoietin-1
- Angiopoietin-2
- Antigens, CD
- Antigens, CD34
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pyrroles
- Vascular Endothelial Growth Factor A
- Atorvastatin
- Leukocyte Common Antigens
|
Topics |
- Aged
- Angiopoietin-1
(blood)
- Angiopoietin-2
(blood)
- Antigens, CD
(blood)
- Antigens, CD34
(blood)
- Atherosclerosis
(blood, drug therapy, pathology)
- Atorvastatin
- Diabetes Mellitus
(blood, drug therapy, pathology)
- Female
- Heptanoic Acids
(therapeutic use)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Leukocyte Common Antigens
(blood)
- Male
- Middle Aged
- Neovascularization, Pathologic
(blood)
- Prospective Studies
- Pyrroles
(therapeutic use)
- Stem Cells
- Vascular Endothelial Growth Factor A
(metabolism)
|